Experts debate whether women at high risk for BC should receive tamoxifen at standard 20 mg dose or can get similar preventive benefit, with fewer toxicities, from lower dose.
Should 5 mg of tamoxifen — known as"baby TAM" — or the usual 20 mg dose be standard of care for breast cancer prevention in high-risk women?
De Censi and colleagues found that baby TAM reduced the risk for invasive breast cancer by 52% and the risk for contralateral breast cancer by 75%.showed ongoing benefits associated with baby TAM vs placebo — a 42% reduction in breast cancer and a 64% drop in contralateral lesions. De Censi said he's surprised the baby TAM vs tamoxifen topic is still being debated."Baby TAM, in my opinion, is a new standard of care for endocrine prevention of breast cancer in high-risk ," and baby TAM over 3 years is enough, said De Censi during a debate on the topic at the 2024 European Society for Medical Oncology Breast Cancer Congress in Berlin.
The vast weight of evidence for tamoxifen prophylaxis, he added, is in trials involving tens of thousands of women, followed in some cases for 20 years, who received the 20 mg dose for 5 years.
Malignant Breast Neoplasm Breast Carcinoma Cancer Malignant Neoplasia Carcinoma Malignant Neoplasm Tamoxifen Selective Estrogen Receptor Modulators SERM - Selective Estrogen Receptor Modulator Endometrial Carcinoma Endometrial Cancer Carcinoma Of The Endometrium Cancer Of The Endometrium Breast Mammary Gland Ovarian Cancer Malignant Ovarian Neoplasm Ovary Cancer
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Jason Leitch joins board of private surgery firmScotland's former national clinical director will advice Elanic Medical on clinical governance.
Read more »
Clinical Wisdom for a New WorldApplying therapists' hard-earned insights in everyday life
Read more »
Should ctDNA Guide Clinical Decisions in Gastrointestinal Cancers?Circulating tumor DNA (ctDNA) has shown increasing promise as a prognostic tool in gastrointestinal cancers.
Read more »
Clinical Trial Of Ketamine Tablets Shows Promising Results For Treatment-Resistant DepressionAnuradha Varanasi is a freelance science writer. She writes on the intersection of health/medicine, racial disparities, and climate change. She earned an MA in Science Journalism from Columbia University in New York City.
Read more »
ASCO 2024: Updates on Clinical Trials in Gynecologic CancersDr Don Dizon highlights new data in gynecologic cancers from the 2024 ASCO Annual Meeting.
Read more »
First Lyme Disease Vaccine in 20 Years Begins Final Clinical Trial—What You Need to KnowA new vaccine to prevent Lyme disease in humans is entering the final phase of clinical trials, manufacturers Pfizer and Valneva announced last week.
Read more »